Healthcare (SH:603313)2025-04-28 07:50Financial Performance - The company's revenue for Q1 2025 reached ¥2,042,802,136.22, representing a year-on-year increase of 12.31% compared to ¥1,818,967,738.44 in the same period last year[7] - Net profit attributable to shareholders was ¥58,719,654.96, a significant increase of 196.22% from ¥19,822,857.37 in the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥58,217,354.58, up 206.80% from ¥18,975,624.85 year-on-year[7] - The basic earnings per share increased to ¥0.10, reflecting a growth of 233.33% compared to ¥0.03 in the same period last year[7] - Operating profit for Q1 2025 was ¥74,572,993.05, significantly up from ¥24,584,907.40 in Q1 2024, marking a growth of 203.5%[18] - Net profit for Q1 2025 was ¥52,918,040.23, compared to ¥21,501,812.37 in Q1 2024, representing an increase of 146.5%[19] - The company achieved a total comprehensive income of ¥75,540,600.74 in Q1 2025, a significant improvement from a loss of ¥18,288,511.37 in Q1 2024[19] - Earnings per share for Q1 2025 was ¥0.10, compared to ¥0.03 in Q1 2024, indicating a 233.3% increase[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥150,630,008.05, an increase of 14.05% from ¥132,075,306.14 in the previous year[7] - Operating cash flow net amount increased to $150.63 million from $132.08 million, representing a growth of 14.0% year-over-year[22] - Total cash inflow from operating activities reached $2.20 billion, up from $2.07 billion, indicating a rise of 6.0%[22] - Cash outflow for operating activities totaled $2.05 billion, an increase from $1.94 billion, marking an increase of 5.6%[22] - Cash and cash equivalents increased to ¥1,029,274,215.09 from ¥1,006,282,974.26, reflecting a growth of about 2.9%[14] - Cash and cash equivalents at the end of the period totaled $843.78 million, slightly down from $866.34 million[23] - Cash inflow from financing activities was $477.77 million, compared to $551.08 million, reflecting a decrease of 13.3%[23] - Cash outflow from financing activities decreased to $641.21 million from $765.52 million, a reduction of 16.2%[23] - The company received $80 million from investment recoveries, indicating a significant cash inflow compared to the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,566,445,291.18, a slight decrease of 0.59% from ¥9,622,769,572.52 at the end of the previous year[8] - The company's current assets totaled ¥4,386,294,881.32, down from ¥4,422,880,344.53 at the end of 2024, indicating a decrease of approximately 0.83%[15] - Total liabilities decreased to ¥5,815,883,828.19 in the latest report from ¥5,936,747,650.29 in the previous period, a reduction of 2.0%[16] - The company's total equity increased to ¥3,750,561,462.99 from ¥3,686,021,922.23, showing a growth of 1.8%[16] - The company's long-term equity investments were valued at ¥55,641,194.52, slightly down from ¥56,457,353.02[15] - The total non-current assets amounted to ¥5,180,150,409.86, a minor decrease from ¥5,199,889,227.99[15] - The company reported a total current liabilities of ¥3,749,345,000.00, reflecting a slight increase compared to previous periods[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,491[11] - Major shareholder Ni Zhanggen holds 33.97% of the shares, with 84,955,100 shares pledged[12] Research and Development - Research and development expenses increased to ¥32,734,895.72 in Q1 2025, up from ¥23,422,099.93 in Q1 2024, reflecting a growth of 39.7%[18] Non-Recurring Gains - The company reported non-recurring gains of ¥502,300.38, primarily from government subsidies and other non-operating income[10]